Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Canntab Therapeutics Ltd CTABF

Canntab Therapeutics Limited is a Canadian phytopharmaceutical company focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations. The Company’s operations comprise a single segment engaged in the medical marijuana business. The Company’s hard pill cannabinoid formulations provide doctors, patients, and consumers with medical grade solutions. These include once a day and extended-release formulations. Its products include INSTANT RELEASE - (IR Tablet), EXTENDED-RELEASE - (XR Tablet), and ORAL DISSOLVING - O.D. Tablet (ODT). The IR Tablet is a release profile for solid hard tablets. The XR Tablet is a phytocannabinoid vehicle that is designed to directly address the drawbacks and challenges of competing oral delivery systems. ODT is specifically designed to dissolve directly in the patient’s mouth, with an onset of action between five and thirty minutes.


PINL:CTABF - Post by User

Canntab Therapeutics Ltd > Emblem News
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by canaken1on Jun 25, 2018 10:22pm
88 Views
Post# 28227658

RE:RE:RE:RE:RE:Emblem News

RE:RE:RE:RE:RE:Emblem NewsTony, In the Oct.2017 license agreement, Emblem & CannTab have agreed to collaborate in developing the XR pill at Emblem's expense and branded as Emblem product. Emblem would have exclusive sales rights in Canada but clearly states that Emblem would not have the right to export. ( It was my opinion that if Emblem exports the XR branded products it will have to be with CannTab's full agreement .)  Not having the full details of the license agreement , I am going to refrain from any further speculations, assumptions or opinions at this stage and say good luck to Emblem longs with the Acnos Phama deal. I have both stocks.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities